A double-blind multicentre study of indapamide in the treatment of essential hypertension

Publisher Website
Google Scholar
Abstract
A double-blind, multicentre trial was carried out in 101 patients with mild to moderate essential hypertension to assess the effectiveness and dose-response relationship of 1 mg or 2 mg indapamide daily, given over a period of 6 weeks. Blood pressure measurements taken before and at the end of each 2-week treatment period showed that there was a significant reduction (p<0.05) in systolic, diastolic and mean blood pressure compared with baseline values in both groups. Although patients receiving 2 mg indapamide daily appeared to show a faster response, the difference between the two groups was not significant. Unwanted effects of treatment did not differ in frequency or severity with increase in dosage, and those symptoms reported were mild in nature. Only 1 patient was withdrawn, because of severe palpitations. Laboratory investigations indicated a tendency towards a decrease in serum potassium and chloride, and an increase in serum uric acid and blood urea nitrogen after treatment, but the levels remained within normal limits.